Ming‐Hao Dong

734 total citations
28 papers, 421 citations indexed

About

Ming‐Hao Dong is a scholar working on Molecular Biology, Neurology and Oncology. According to data from OpenAlex, Ming‐Hao Dong has authored 28 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Neurology and 9 papers in Oncology. Recurrent topics in Ming‐Hao Dong's work include Neuroinflammation and Neurodegeneration Mechanisms (10 papers), CAR-T cell therapy research (6 papers) and MicroRNA in disease regulation (4 papers). Ming‐Hao Dong is often cited by papers focused on Neuroinflammation and Neurodegeneration Mechanisms (10 papers), CAR-T cell therapy research (6 papers) and MicroRNA in disease regulation (4 papers). Ming‐Hao Dong collaborates with scholars based in China, United States and Germany. Ming‐Hao Dong's co-authors include Luo‐Qi Zhou, Dai‐Shi Tian, Chuan Qin, Wei Wang, Jun Xiao, Yun‐Fan You, Ke Shang, Yun‐Hui Chu, Min Zhang and Wen Wang and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Brain.

In The Last Decade

Ming‐Hao Dong

27 papers receiving 419 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ming‐Hao Dong China 13 134 125 110 101 49 28 421
Ani Solanki United States 10 82 0.6× 184 1.5× 130 1.2× 40 0.4× 24 0.5× 31 405
Xiuzhi Jia China 13 50 0.4× 136 1.1× 120 1.1× 37 0.4× 19 0.4× 30 405
Jennifer Hahn Canada 10 63 0.5× 182 1.5× 91 0.8× 50 0.5× 27 0.6× 12 345
Junnian Zheng China 10 116 0.9× 110 0.9× 180 1.6× 31 0.3× 32 0.7× 12 371
Paulo Niemeyer Filho Brazil 12 141 1.1× 221 1.8× 53 0.5× 58 0.6× 162 3.3× 31 754
Yuefei Yu United States 14 120 0.9× 266 2.1× 236 2.1× 34 0.3× 21 0.4× 29 476
Aihua Sun China 16 93 0.7× 259 2.1× 100 0.9× 48 0.5× 21 0.4× 54 629
Morteza Abouzaripour Iran 8 162 1.2× 191 1.5× 237 2.2× 31 0.3× 18 0.4× 15 526
Wanyong Yang China 11 46 0.3× 190 1.5× 48 0.4× 37 0.4× 29 0.6× 16 360
Lauren Dong United States 6 80 0.6× 141 1.1× 87 0.8× 28 0.3× 10 0.2× 13 455

Countries citing papers authored by Ming‐Hao Dong

Since Specialization
Citations

This map shows the geographic impact of Ming‐Hao Dong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming‐Hao Dong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming‐Hao Dong more than expected).

Fields of papers citing papers by Ming‐Hao Dong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming‐Hao Dong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming‐Hao Dong. The network helps show where Ming‐Hao Dong may publish in the future.

Co-authorship network of co-authors of Ming‐Hao Dong

This figure shows the co-authorship network connecting the top 25 collaborators of Ming‐Hao Dong. A scholar is included among the top collaborators of Ming‐Hao Dong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming‐Hao Dong. Ming‐Hao Dong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pang, Xiao‐Wei, Lifang Zhu, Ming‐Hao Dong, et al.. (2025). Circulating insulin-like growth factor-1 and the risk of multiple sclerosis: a prospective cohort study. Multiple Sclerosis and Related Disorders. 94. 106281–106281.
2.
Zhang, Hang, Luo‐Qi Zhou, Sheng Yang, et al.. (2025). The foam cell-derived exosomes exacerbate ischemic white matter injury via transmitting metabolic defects to microglia. Cell Metabolism. 37(8). 1636–1654.e10. 2 indexed citations
3.
Dong, Ming‐Hao, Luo‐Qi Zhou, Michael Heming, et al.. (2025). Anti-BCMA CAR-T cell therapy in relapsed/refractory chronic inflammatory demyelinating polyneuropathy. Med. 6(9). 100704–100704. 2 indexed citations
4.
Zhu, Lifang, Luyang Zhang, Yun‐Hui Chu, et al.. (2024). Causal association between the peripheral immunity and the risk and disease severity of multiple sclerosis. Frontiers in Immunology. 15. 1325938–1325938. 1 indexed citations
5.
Tian, Dai‐Shi, Chuan Qin, Ming‐Hao Dong, et al.. (2024). B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis. EMBO Molecular Medicine. 16(4). 966–987. 30 indexed citations
6.
Qin, Chuan, Ming‐Hao Dong, Luo‐Qi Zhou, et al.. (2024). Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy. Proceedings of the National Academy of Sciences. 121(6). e2315990121–e2315990121. 42 indexed citations
7.
You, Yun‐Fan, Ming‐Hao Dong, Xiao‐Wei Pang, et al.. (2024). Systematic Druggable Genome‐Wide Mendelian Randomization Identifies Therapeutic Targets for Functional Outcome After Ischemic Stroke. Journal of the American Heart Association. 13(16). e034749–e034749. 2 indexed citations
8.
Dong, Ming‐Hao, Xiao‐Wei Pang, Hang Zhang, et al.. (2024). Macrophage exosomal miR-30c-2-3p in atherosclerotic plaques aggravates microglial neuroinflammation during large-artery atherosclerotic stroke via TGF-β/SMAD2 pathway. Journal of Neuroinflammation. 21(1). 292–292. 9 indexed citations
9.
Zhang, Hang, Sheng Yang, Yilin Lu, et al.. (2024). Microglial Nrf2-mediated lipid and iron metabolism reprogramming promotes remyelination during white matter ischemia. Redox Biology. 79. 103473–103473. 6 indexed citations
10.
Qin, Chuan, Ming‐Hao Dong, Yue Tang, et al.. (2024). The foam cell-derived exosomal miRNA Novel-3 drives neuroinflammation and ferroptosis during ischemic stroke. Nature Aging. 4(12). 1845–1861. 10 indexed citations
11.
Qin, Chuan, Sheng Yang, Man Chen, et al.. (2023). Modulation of microglial metabolism facilitates regeneration in demyelination. iScience. 26(5). 106588–106588. 13 indexed citations
12.
Zhou, Luo‐Qi, et al.. (2023). Potential therapeutic targets for sarcopenia identified by Mendelian randomisation. Age and Ageing. 52(2). 16 indexed citations
13.
Qin, Chuanbo, Man Chen, Yun‐Hui Chu, et al.. (2023). TREM2‐IGF1 Mediated Glucometabolic Enhancement Underlies Microglial Neuroprotective Properties During Ischemic Stroke. Advanced Science. 11(10). e2305614–e2305614. 23 indexed citations
14.
Qin, Chuan, Dai‐Shi Tian, Luo‐Qi Zhou, et al.. (2023). Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduction and Targeted Therapy. 8(1). 5–5. 93 indexed citations
15.
Qin, Chuanbo, Man Chen, Ming‐Hao Dong, et al.. (2023). Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders. Brain. 147(1). 163–176. 20 indexed citations
16.
Dong, Ming‐Hao, Luo‐Qi Zhou, Man Chen, et al.. (2022). CSF sTREM2 in neurological diseases: a two-sample Mendelian randomization study. Journal of Neuroinflammation. 19(1). 79–79. 17 indexed citations
17.
Zhou, Yuhao, et al.. (2021). Whole-Exome Sequencing Reveals Novel Variations in Patients with Familial Von Hippel−Lindau Syndrome. World Neurosurgery. 150. e696–e704. 1 indexed citations
18.
Dong, Ming‐Hao, Feng He, & Yu Deng. (2020). How to Understand Herd Immunity in the Context of COVID-19. Viral Immunology. 34(3). 174–181. 16 indexed citations
19.
Zhan, Qi, et al.. (2019). The Coexistence of Gliosarcoma and Arteriovenous Malformation with the BRAF V600E Mutation. World Neurosurgery. 134. 594–597. 1 indexed citations
20.
Wang, Zhengchao, Hongmei Li, Ming‐Hao Dong, Pengfei Zhu, & Yu Cai. (2019). The anticancer effects and mechanisms of fucoxanthin combined with other drugs. Journal of Cancer Research and Clinical Oncology. 145(2). 293–301. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ani Solanki Breakdown of academic impact, for papers by Xiuzhi Jia Breakdown of academic impact, for papers by Jennifer Hahn Breakdown of academic impact, for papers by Junnian Zheng Breakdown of academic impact, for papers by Paulo Niemeyer Filho Breakdown of academic impact, for papers by Yuefei Yu Breakdown of academic impact, for papers by Aihua Sun Breakdown of academic impact, for papers by Morteza Abouzaripour Breakdown of academic impact, for papers by Wanyong Yang Breakdown of academic impact, for papers by Lauren Dong
Rankless by CCL
2026